Wilex AG has announced the start of a Phase 1b/2 trial in patients with solid tumours of its experimental drug that inhibits the mitogen-activated protein kinase (MEK). The study will be conducted in the UK. ---Subscribe to MedNous to access this article--- Company News Research & University News
